Clinical application of DEX/CRH test and multi-channel NIRS in patients with depression

Kinoshita, Shinya; Kanazawa, Tetsufumi; Kikuyama, Hiroki; Yanagawa, Hiroshi

doi:10.1186/s12993-016-0108-x

Cited by 12 publications

(11 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This non-expected low incidence—especially in depressed SADs and BDs—is nonetheless in accordance with some previous but not all reports [for review, see ( 3 )]. We could presume that the sensitivity in detecting HPA axis overactivity would be better using the combined dexamethasone/corticotropin-releasing hormone (DEX/CRH) test ( 48 – 50 ), although all studies do not agree ( 51 , 52 ). It has been hypothesized that the hyperactivity of the HPA axis is primarily a reflection of abnormal limbic-hypothalamic activation, with increased secretion of hypothalamic CRH and consequent excessive adrenal cortisol secretion ( 17 ).…”

Section: Discussionmentioning

confidence: 99%

Dopaminergic, Noradrenergic, Adrenal, and Thyroid Abnormalities in Psychotic and Affective Disorders

et al. 2020

View full text Add to dashboard Cite

Background: This study aimed to assess hypothalamic-pituitary dopaminergic (DA), noradrenergic (NA), thyroid (HPT), and adrenal (HPA) activity in schizophrenia, in schizoaffective disorder, and in bipolar disorder. Method: We investigated a combined approach of hormone responses to (1) apomorphine (APO), a short-acting DA receptor agonist which decreases prolactin secretion (PRL), and stimulates secretion of growth hormone (GH), adrenocorticotropin (ACTH), and cortisol; (2) clonidine (CLO), an alpha 2-adrenoceptor agonist which stimulates GH secretion; (3) 8 AM and 11 PM protirelin (TRH) which stimulates thyrotropin (TSH) secretion; and (4) dexamethasone which suppresses cortisol secretion, in 13 hospitalized healthy male controls and 39 untreated male inpatients: 13 with DSM-IV paranoid schizophrenia, 13 with DSM-IV schizoaffective disorder (bipolar subtype, depressed at the time of the study), and 13 with DSM-IV bipolar disorder (depressed). Results: Compared to controls, paranoid schizophrenic patients showed (1) lower APOinduced ACTH and cortisol stimulation, and (2) higher post-dexamethasone cortisol values. Compared to controls, schizoaffective and bipolar patients showed (1) lower DDTSH values (i.e., difference between 11 PM and 8 AM TRH-TSH responses), (2) lower APO-induced PRL suppression, (3) lower CLO-induced GH stimulation, and (4) higher post-dexamethasone cortisol values. Conclusions: Although results must be interpreted with caution because of the small sample, this preliminary study suggests that depressed bipolar and schizoaffective patients share common biological dysregulations, distinct from that of paranoid schizophrenic patients. From a pathophysiological viewpoint, paranoid schizophrenic patients can be characterized by hyposensitivity of the hypothalamic DA receptors (possibly resulting from an increase in presynaptic DA release) associated with increased HPA axis activity, while depressed bipolar and schizoaffective patients can be characterized by hyposensitivity of the pituitary TRH and DAD 2 receptors (possibly linked

show abstract

Section: Discussionmentioning

confidence: 99%

Dopaminergic, Noradrenergic, Adrenal, and Thyroid Abnormalities in Psychotic and Affective Disorders

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Almost all of the studies did not indicate the specificity and sensitivity of differentiating between depressed patients and HCs, with the exception of one that indicated an 80% sensitivity but with its specificity being unspecified (29). One study had indicated a sensitivity of 71.5% and a specificity of 70% for differentiating depressed patients from those with Alzheimer's disease (30), and another study mentioned a sensitivity of 0.71 and a specificity of 0.46 to distinguish between the euthymic, unipolar and bipolar depressive patients (37).…”

Section: Use Of Fnirs To Differentiate Depressed From Healthy Individmentioning

confidence: 99%

Diagnostic and Predictive Applications of Functional Near-Infrared Spectroscopy for Major Depressive Disorder: A Systematic Review

et al. 2020

View full text Add to dashboard Cite

Introduction: Major depressive disorder (MDD) is a global psychiatric disorder with no established biomarker. There is growing evidence that functional near-infrared spectroscopy (fNIRS) has the ability to aid in the diagnosis and prediction of the treatment response of MDD. The aim of this review was to systematically review, and gather the evidence from existing studies that used fNIRS signals in the diagnosis of MDD, correlations with depression symptomatology, and the monitoring of treatment response. Methods: PubMed, EMBASE, ScienceDirect, and Cochrane Library databases were searched for published English articles from 1980 to June 2019 that focused on the application of fNIRS for (i) differentiating depressed versus nondepressed individuals, (ii) correlating with depression symptomatology, and in turn (iii) monitoring treatment responses in depression. Studies were included if they utilized fNIRS to evaluate cerebral hemodynamic variations in patients with MDD of any age group. The quality of the evidence was assessed using the Newcastle-Ottawa quality assessment scale. Results: A total of 64 studies were included in this review, with 12 studies being longitudinal, while the rest were cross-sectional. More than two-thirds of the studies (n = 49) had acceptable quality. fNIRS consistently demonstrated attenuated cerebral hemodynamic changes in depressed compared to healthy individuals. fNIRS signals have also shown promise in correlating with individual symptoms of depression and monitoring various treatment responses. Conclusions: This review provides comprehensive updated evidence of the diagnostic and predictive applications of fNIRS in patients with MDD. Future studies involving larger

show abstract

“…127 Depressed patients who exhibited nonsuppressive e®ects in response to the administration of dexamethasone and corticotropin-releasing hormone showed signi¯cant di®erences in fNIRS responses when compared to the patients who exhibited suppressive behavior. 128 BD and MDD patients with family histories of psychiatric diseases showed highly impaired activation in the PFC compared to those without family histories of psychiatric diseases. 129 MDD patients with positive responsiveness to selective serotonin reuptake inhibitors showed a signi¯cantly higher HbO response compared to nonresponsive MDD patients.…”

Section: Verbal°uency Taskmentioning

confidence: 87%

“…Patients are usually classi¯ed based on the impaired hemodynamic responses caused due to some disease. [128][129][130][131][132][133] The localization of an impairment in the brain is a vital step to evaluate the intensity and type of the disease. Therefore, the placement of fNIRS sources, detectors, or optodes on a patient's head based on the task involved is important as most tasks are associated with known brain regions.…”

Section: Channel Localizationmentioning

confidence: 99%

Application of functional near-infrared spectroscopy in the healthcare industry: A review

Hong

Yaqub

2019

J. Innov. Opt. Health Sci.

View full text Add to dashboard Cite

Functional near-infrared spectroscopy (fNIRS), a growing neuroimaging modality, has been utilized over the past few decades to understand the neuronal behavior in the brain. The technique has been used to assess the brain hemodynamics of impaired cohorts as well as able-bodied. Neuroimaging is a critical technique for patients with impaired cognitive or motor behaviors. The portable nature of the fNIRS system is suitable for frequent monitoring of the patients who exhibit impaired brain activity. This study comprehensively reviews brain-impaired patients: The studies involving patient populations and the diseases discussed in more than 10 works are included. Eleven diseases examined in this paper include autism spectrum disorder, attention-deficit hyperactivity disorder, epilepsy, depressive disorders, anxiety and panic disorder, schizophrenia, mild cognitive impairment, Alzheimer’s disease, Parkinson’s disease, stroke, and traumatic brain injury. For each disease, the tasks used for examination, fNIRS variables, and significant findings on the impairment are discussed. The channel configurations and the regions of interest are also outlined. Detecting the occurrence of symptoms at an earlier stage is vital for better rehabilitation and faster recovery. This paper illustrates the usability of fNIRS for early detection of impairment and the usefulness in monitoring the rehabilitation process. Finally, the limitations of the current fNIRS systems (i.e., nonexistence of a standard method and the lack of well-established features for classification) and future research directions are discussed. The authors hope that the findings in this paper would lead to advanced breakthrough discoveries in the fNIRS field in the future.

show abstract

Clinical application of DEX/CRH test and multi-channel NIRS in patients with depression

Cited by 12 publications

References 41 publications

Dopaminergic, Noradrenergic, Adrenal, and Thyroid Abnormalities in Psychotic and Affective Disorders

Dopaminergic, Noradrenergic, Adrenal, and Thyroid Abnormalities in Psychotic and Affective Disorders

Diagnostic and Predictive Applications of Functional Near-Infrared Spectroscopy for Major Depressive Disorder: A Systematic Review

Application of functional near-infrared spectroscopy in the healthcare industry: A review

Contact Info

Product

Resources

About